[go: up one dir, main page]

Wirths et al., 2010 - Google Patents

Alzheimer disease (AD) represents the most frequent form of dementia and is

Wirths et al., 2010

View PDF
Document ID
2256376114353470587
Author
Wirths O
Erck C
Martens H
Harmeier A
Geumann C
Jawhar S
Kumar S
Multhaup G
Walter J
Ingelsson M
Degerman-Gunnarsson M
Kalimo H
Huitinga I
Lannfelt L
Bayer T
Publication year

External Links

Snippet

neurofibrillary tangles. The discovery that certain early-onset familial forms of AD may be caused by enhanced levels of Aβ peptides have led to the hypothesis that amyloidogenic Aβ is intimately involved in the AD pathogenic process (1). In the past extracellular Aβ has been …
Continue reading at www.radio-utopie.de (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Wirths et al. Identification of low molecular weight pyroglutamate Aβ oligomers in Alzheimer disease: a novel tool for therapy and diagnosis
US8795664B2 (en) Monoclonal antibodies targeting amyloid beta oligomers
Wirths et al. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
Dufty et al. Calpain-cleavage of α-synuclein: connecting proteolytic processing to disease-linked aggregation
Rohn et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer’s disease
Tampellini et al. Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations
DK2361638T3 (en) Beta-1-42-specific monoclonal antibodies with therapeutic properties
EP2470211B1 (en) Antibodies that bind tau oligomers
Sokolow et al. AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly
KR101602546B1 (en) Antibody, kit and method for determining amyloid peptides
Wirths et al. N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models
EP2847217B1 (en) CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta
MX2007010934A (en) Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody.
Fonseca et al. The presence of isoaspartic acid in β-amyloid plaques indicates plaque age
Ward et al. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy
Herline et al. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer’s disease mouse model
Colvin et al. The conformational epitope for a new Aβ42 protofibril‐selective antibody partially overlaps with the peptide N‐terminal region
Upadhyay et al. Amyloid fibril proteomics of AD brains reveals modifiers of aggregation and toxicity
Saul et al. Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias
Perez-Garmendia et al. Identification of N-terminally truncated pyroglutamate amyloid-β in cholesterol-enriched diet-fed rabbit and AD brain
US20090317380A1 (en) Use of prion conversion modulating agents
Härtig et al. Concomitant detection of β-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice
JP2010505089A (en) Screening method for compounds having anti-amyloid properties
Wirths et al. Alzheimer disease (AD) represents the most frequent form of dementia and is
US9011862B2 (en) Inhibitors of the nitration of amyloid β peptides and their uses in the diagnosis and treatment of Alzheimer's disease